Cognition Therapeutics, Inc. (CGTX) Stock Score, Valuation & Financial Research

Cognition Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for CGTX

Cognition Therapeutics, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 0.96. These figures are a research snapshot, not a buy or sell recommendation.

What Cognition Therapeutics, Inc. does

Cognition Therapeutics, Inc. is a biopharmaceutical company in the clinical stage, focused on identifying and advancing small molecule treatments. The firm's research and development efforts are primarily directed towards age-related neurodegenerative conditions affecting the central nervous system, as well as retinal disorders. Its most advanced experimental therapy is CT1812, which acts as a sigma-2 receptor antagonist. This compound is currently being evaluated in Phase II clinical trials for the management of mild-to-moderate Alzheimer's disease and dementia with Lewy bodies (DLB). Additionally, it has successfully concluded Phase I trials for early-stage Alzheimer's and is undergoing preclinical investigation for dry age-related macular degeneration (AMD). The company's pipeline also includes CT2168, a treatment candidate for synucleinopathies—a category of diseases encompassing DLB and Parkinson's disease—and CT2074, which is in development for dry AMD. Cognition Therapeutics, Inc. was established in 2007 and operates from its headquarters in Purchase, New York.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Cognition Therapeutics is a clinical-stage biopharmaceutical company that does not currently generate revenue from product sales. Its business model relies on raising capital through equity offerings and potential future licensing or collaboration agreements to fund the research and development of small molecule therapeutics for CNS and retinal diseases.

Products and services

  • The company is developing a pipeline of small molecule candidates, including zervimesine (CT1812), which is being studied for Alzheimer's disease, dementia with Lewy bodies, and dry age-related macular degeneration.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) — The company relies on third-party vendors for clinical trial management, data collection, and the manufacturing of drug candidates; specific supplier names are not disclosed. Source

Business relationships and partnerships

  • Alzheimer’s Clinical Trial Consortium (ACTC) — A collaboration with the NIA-funded clinical trials network to conduct the START clinical trial for Alzheimer's disease. Source

Business strengths to evaluate

  • Proprietary pipeline targeting age-related degenerative diseases Source

Business risks and research considerations

  • History of operating losses and dependence on additional financing Source
  • Clinical trial failure or regulatory delays Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

CGTX financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 0.96
Market capitalization:
85.92M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -16.78M
Free cash flow:
USD -24.59M
Cash:
USD 34.01M
Total debt:
USD 511K
EPS:
USD -0.19

What stands out

  • Free cash flow is USD -24.59M, negative for the stored period.
  • The balance sheet shows USD 34.01M of cash versus USD 511K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 33.5M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for CGTX

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can CGTX fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is CGTX likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for CGTX to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of CGTX's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research CGTX

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.